Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 28141 - 28160 out of 498429 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Australia | (S01KA02) hypromellose | Revive Tears 0.3% w/w eye drops, 10 mL | Eye drops 3 mg per mL, 10 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
n/a | PetrusPharmaceuticalsPtyLtd |
| Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 1.65 mg/0.165 mL injection, 0.165 mL syringe | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA04) ranibizumab | Lucentis 2.3 mg/0.23 mL injection, 0.23 mL vial | Solution for intravitreal injection 2.3 mg in 0.23 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | NovartisPharmaceuticalsAustraliaPtyLimited |
| Australia | (S01LA05) aflibercept | Eylea 8 mg/0.07 mL injection, 0.07 mL vial | Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 8 mg/0.07 mL injection, 0.07 mL vial | Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
| Australia | (S01LA05) aflibercept | Eylea 8 mg/0.07 mL injection, 0.07 mL vial | Solution for intravitreal injection 11.43 mg in 100 microlitres (114.3 mg per mL), 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization | BayerAustraliaLtd |
Pages
